Download PDF
Nuklearmedizin 1988; 27(01): 8-11
DOI: 10.1055/s-0038-1628903
Originalarbeiten — Original Articles
Schattauer GmbH

Localization of 99mTc-Diphosphonates in Newly Formed Bone Matrix as a Measure of Bone Lesion Detectability[*]

C. Schuemichen
1   From the Department of Nuclear Medicine, University Clinic of Radiology, Albert-Ludwigs-University, Freiburg i. Br., FRG
,
Th. Krause
1   From the Department of Nuclear Medicine, University Clinic of Radiology, Albert-Ludwigs-University, Freiburg i. Br., FRG
,
G. Umbach
1   From the Department of Nuclear Medicine, University Clinic of Radiology, Albert-Ludwigs-University, Freiburg i. Br., FRG
,
T. Wolff
1   From the Department of Nuclear Medicine, University Clinic of Radiology, Albert-Ludwigs-University, Freiburg i. Br., FRG
› Author Affiliations
Further Information

Publication History

Received: 17 December 1987

Publication Date:
04 February 2018 (online)

Also available at
    Permissions and Reprints

The lesion-to-normal-bone ratios of DBA-MDP (dibutylamino-methylene-diphosphonate), DPD (dicarboxypropane-diphosphonate) and MDP (methylene-diphosphonate) each labeled with 99mTc, were evaluated in experimental bone lesions. In 3-day old lesions this ratio was increased twofold for DBA-MDP in comparison with MDP and DPD which showed nearly equal ratios. Later on these differences became negligibly small. It is concluded that 99mTc-DBA-MDP is fixed more strongly in the immature bone matrix and that this will lead to an improvement in the detectability of lesions containing larger amounts of immature bone matrix.

Zusammenfassung

Das Anreicherungsverhältnis zwischen experimentellen Knochenläsionen und normalem Knochen wurde für 99mTc-markiertes DBA-MDP (Dibutylamino-Methylen-Diphosphonat), DPD (Dicarboxypropan-Diphosphonat) und MDP (Methylen-Diphosphonat) gemessen. Bei 3 Tage alten Läsionen war dieses Verhältnis bei 99mTc-DBA-MDP um das Zweifache gegenüber MDP und DPD erhöht. Später wurden diese Unterschiede vernachlässigbar klein. Es wird die Schlußfolgerung gezogen, daß 99mTc-DBA-MDP in der unreifen Knochenmatrix stärker fixiert wird, und daß deshalb die Nachweiswahrscheinlichkeit von Knochenläsionen, die größere Mengen an unreifer Knochenmatrix enthalten, verbessert wird.

* Dedicated to Professor Dr. G. Löhr on the occasion of his 65th birthday.


 

  • REFERENCES

  • 1 Adler C-P. Knochenkrankheiten: Diagnostik makroskopischer, histologischer und radiologischer Strukturveränderungen des Skeletts. Stuttgart - New York: Thieme; 1983
    Search in Google Scholar
  • 2 Büll U, Kleinhans E, Zorn-Bopp E. et al. A comparison of bone imaging with 99mTc DPD and 99mTc MDP. J Nucl Med 1982; 23: 214-7.
    PubMedSearch in Google Scholar
  • 3 Charkes N D. Mechanisms of skeletal tracer uptake. J Nucl Med 1979; 20: 794-5.
    PubMedSearch in Google Scholar
  • 4 Delaloye B, Delaloye-Bischof A, Dudczak R. et al. Clinical comparison of 99mTc-HMDP and 99mTc-MDP A multicenter study. Eur J Nucl Med 1985; 11: 182-5.
    PubMedSearch in Google Scholar
  • 5 Fogelman I, Citrin D L, McKillop J H. et al. A clinical comparison of 99mTc HEDP and 99mTc MDP in the detection of bone metastases. J Nucl Med 1979; 20: 98-101.
    PubMedSearch in Google Scholar
  • 6 Guillemart A, Le Pape A, Galy G, Besnard J-C. Bone kinetics of calcium-45 and pyrophosphate labeled with technetium-96. An autoradiographic evaluation. J Nucl Med 1980; 21: 466-70.
    PubMedSearch in Google Scholar
  • 7 Pauwels E K J, Blom J, Camps J A J, Hermans J, Rijke A M. A comparison between the diagnostic efficacy of 99mTc-MDP and 99mTc-HDP for the detection of bone metastases. Eur J Nucl Med 1983; 08: 118-22.
    Search in Google Scholar
  • 8 Rosenthall L, Stern J, Arzoumanian A. A clinical comparison of MDP and DMAD. Clin Nucl Med 1982; 07: 403-6.
    CrossrefPubMedSearch in Google Scholar
  • 9 Schwarz A, Kloss G. Technetium-99m-DPD - a new skeletal imaging agent. J Nucl Med 1981; 22: 77.
    Search in Google Scholar
  • 10 Schümichen C, Mundriziewski L, Tischler E, Hoffmann G. Relationship between blood flow and radiostrontium uptake in the healing bone fracture. Eur J Nucl Med 1979; 04: 413-7.
    CrossrefPubMedSearch in Google Scholar
  • 11 Schümichen C, Rempfle H, Wagner M, Hoffmann G. The short-term fixation of radiopharmaceuticals in bone. Eur J Nucl Med 1979; 04: 423-8.
    CrossrefPubMedSearch in Google Scholar
  • 12 Schümichen C, Koch K, Kraus A. et al. Binding of technetium-99m to plasma proteins. Influence on the distribution of Tc-99m phosphate agents. J Nucl Med 1980; 21: 1080-5.
    PubMedSearch in Google Scholar
  • 13 Schümichen C, Schmidt H, Koutsomanis D. 99mTc DPD (dicarboxypropane diphosphonate), mechanism of bone uptake and renal excretion. J Nucl Med 1982; 23: 77.
    Search in Google Scholar
  • 14 Schümichen C. Physiologische Grundlagen der Knochenszintigraphie; Meßtechnik und quantitative Auswertung. Der Nuklearmediziner 1984; 02: 73-88.
    Search in Google Scholar
  • 15 Smith M L, Martin W, McKillop J H. et al. Improved lesion detection with dimethylamino-diphosphonate. A report of two cases. Eur J Nucl Med 1984; 09: 519-20.
    CrossrefPubMedSearch in Google Scholar
  • 16 Subramanian G, McAfee J G, Blair R J, Thomas F D, Kallfelz E A. 99mTc-methylene diphosphonate - a superior agent for skeletal imaging: Comparison with other 99mTc-complexes. J Nucl Med 1975; 16: 744.
    PubMedSearch in Google Scholar
  • 17 Unterspann S, Finck W. Chemical structure and pharmacokinetics of 99mTc-labelled aminomethane diphosphonic acid derivatives. Eur J Nucl Med 1981; 06: 527.
    Search in Google Scholar
  • 18 Vaughan J M. The physiology of bone. Clarendon Press; Oxford: 1975
    Search in Google Scholar
  • 19 Vorne M, Vähätalo S, Lantto T. A clinical comparison of 99mTc-DPD and two 99mTc-MDP agents. Eur J Nucl Med 1983; 08: 395-7.
    Search in Google Scholar
  • 20 Wilson G M, Pinkerton T C. Determination of charge and size of technetium diphosphonate complexes by anion-exchange liquid chromatography. Anal Chem 1985; 57: 246.
    CrossrefSearch in Google Scholar